Liquidia Technologies Inc(LQDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LQDA Liquidia Technologies Inc

Trading 03-28 13:35:05 EDT

15.09

-0.15

-1.02%

High15.59	Low15.08	Vol262.28K
Open15.27	D1 Closing15.24	Amplitude3.35%
Mkt Cap1.29B	Tradable Cap998.77M	Total Shares85.30M
T/O4.03M	T/O Rate0.40%	Tradable Shares66.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LQDA","market":"US","secType":"STK","nameCN":"Liquidia Technologies Inc","latestPrice":15.085,"timestamp":1743183300884,"preClose":15.24,"halted":0,"volume":262280,"delay":0,"floatShares":66209807,"shares":85298537,"eps":-1.65669,"marketStatus":"Trading","change":-0.155,"latestTime":"03-28 13:35:05 EDT","open":15.27,"high":15.59,"low":15.08,"amount":4030590.5228,"amplitude":0.033465,"askPrice":15.1,"askSize":353,"bidPrice":15.06,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.65669,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1532577600000,"exchange":"NASDAQ","adjPreClose":15.24,"preHourTrading":{"tag":"盘前","latestPrice":14.88,"preClose":15.24,"latestTime":"08:15 EDT","volume":315,"amount":4681.19988,"timestamp":1743164158534},"postHourTrading":{"tag":"盘后","latestPrice":15.24,"preClose":15.24,"latestTime":"16:24 EDT","volume":21184,"amount":322844.17,"timestamp":1743107059409},"volumeRatio":0.564513,"impliedVol":0.1152,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/LQDA","defaultTab":"news","newsList":[{"id":"2522570814","title":"Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2522570814","media":"GlobeNewswire","labels":["productRelease"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2522570814?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:30","pubTimestamp":1743168600,"startTime":"0","endTime":"0","summary":"MORRISVILLE, N.C., March 28, 2025  -- Liquidia Corporation , a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration  has accepted its New Drug Application  resubmission for YUTREPIA  inhalation powder to treat pulmonary arterial hypertension  and pulmonary hypertension associated with interstitial lung disease . The FDA confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA for both PAH and PH-ILD. The FDA has set a Prescription Drug User Fee Act  goal date of May 24, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/liquidia-corporation-announces-fda-acceptance-133000463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2522050821","title":"Liquidia Says FDA to Review New Drug Application for Yutrepia","url":"https://stock-news.laohu8.com/highlight/detail?id=2522050821","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522050821?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 22:04","pubTimestamp":1743170646,"startTime":"0","endTime":"0","summary":"Liquidia  said Friday the US Food and Drug Administration accepted its resubmitted new drug application for Yutrepia inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.The company said the FDA classified the resubmission as a complete, Class 1 response to an August 2024 action letter that granted tentative approval of Yutrepia, or treprostinil.The agency set a May 24 target action date, Liquidia said.Shares of the company were up 1.5% in recent trading Friday.Price: 15.47, Change: +0.23, Percent Change: +1.48","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA","BK4007"],"gpt_icon":0},{"id":"2522773025","title":"Liquidia Corp - FDA Sets Pdufa Goal Date of May 24, 2025 for Yutrepia","url":"https://stock-news.laohu8.com/highlight/detail?id=2522773025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522773025?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:30","pubTimestamp":1743168649,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA8NRFW0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2522457758","title":"Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for Yutrepia™ (Treprostinil) Inhalation Powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2522457758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522457758?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:30","pubTimestamp":1743168649,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nTUA8NRFW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2522724903","title":"Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2522724903","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522724903?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"- Data from the ASCENT study of LIQ861  in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life. - Case study highlights the long-term safety and tolerability of LIQ861  in a PAH patient transitioning from parenteral treprostinil in INSPIRE study. MORRISVILLE, N.C., March 27, 2025  -- Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,today announced the company will present three posters at the AmericanThoracic Society  2025 International Conference, taking placeMay 18-21, 2025, inSan Francisco. Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861  in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk distance, quality of life, and changes in cardiac effort. A third poster is a case study of a patient with PAH participating in the open-label extension stu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/liquidia-announces-poster-presentations-american-120000468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATS","BK4007","AFG","BK4107","LQDA","BK4161","BK4117"],"gpt_icon":0},{"id":"2522703907","title":"Discover 3 Top Growth Companies With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2522703907","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522703907?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 01:05","pubTimestamp":1742835933,"startTime":"0","endTime":"0","summary":"As the United States market experiences a rally with major indices like the S&P 500 and Nasdaq posting gains, investor sentiment is buoyed by reports of potential tariff reductions. In this environment, growth companies with significant insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the company's operations and prospects.Top 10 Growth Companies With High Insider Ownership In The United States. Click here to see the full list of 205 stocks from our Fast Growing US Companies With High Insider Ownership screener.AlTi Global is projected to achieve profitability in the next three years, with earnings expected to grow at 119.26% annually, surpassing market averages. Despite this growth potential, recent financials show a decline in revenue and continued net losses. The company has undergone executive changes with the appointment of Mike Harrington as CFO, bringing extensive financial services experience. While insider trading d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-3-top-growth-companies-170533972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1791807156.HKD","BK4588","TBBB","LU2360107671.USD","BHC","BK4007","BK4585","LQDA","ALTI","DFS","LU1668664300.SGD","BK4113","LU1861220207.SGD","LU1861217088.USD","BK4135","BK4196","BK4166","LU0106831901.USD"],"gpt_icon":1},{"id":"2520045543","title":"Liquidia price target lowered to $22 from $23 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2520045543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520045543?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:15","pubTimestamp":1742472935,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Liquidia (LQDA) to $22 from $23 and keeps a Buy rating on the shares following a Q4 update that the firm sa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liquidia-price-target-lowered-to-22-from-23-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liquidia-price-target-lowered-to-22-from-23-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LQDA","BK4007"],"gpt_icon":0},{"id":"2520434021","title":"Liquidia Price Target Maintained With a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434021","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434021?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:40","pubTimestamp":1742467200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LQDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:40 ET (10:40 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"gpt_icon":0},{"id":"2520317864","title":"Liquidia Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2520317864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520317864?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:17","pubTimestamp":1742465820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LQDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:17 ET (10:17 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"gpt_icon":0},{"id":"2520613436","title":"Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Liquidia Technologies (LQDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520613436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520613436?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 17:30","pubTimestamp":1742463053,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and Liqu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbott-laboratories-abt-and-liquidia-technologies-lqda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbott-laboratories-abt-and-liquidia-technologies-lqda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","SGXZ23171101.USD","LU2237957811.SGD","LU2237957902.USD","LU1989763690.USD","IE00BJJMRZ35.SGD","BK4504","LU1691799644.USD","IE0002141913.USD","SG9999004303.SGD","BK4581","ABT","LU2133065610.SGD","IE00BFTCPJ56.SGD","BK4588","LU1061106388.HKD","SG9999002224.SGD","LU2112291526.USD","LU0234572021.USD","IE00B2B36J28.USD","BK4137","LU1721429741.USD","LU0170899867.USD","LQDA","BK4566","SG9999002232.USD","LU2089984988.USD","BK4568","IE00B4R5TH58.HKD","LU1023059063.AUD","LU2468319806.SGD","BK4007","BK4585","BK4592","LU1057294990.SGD","BK4533","IE00BJT1NW94.SGD","BK4082","LU0122379950.USD","LU1721429402.USD","LU1914381329.SGD","LU1989763427.SGD","LU0266013472.USD","LU0868494617.USD","HCSG"],"gpt_icon":0},{"id":"2520482301","title":"Liquidia Files Secondary Common Stock Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2520482301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520482301?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 16:45","pubTimestamp":1742460342,"startTime":"0","endTime":"0","summary":"Liquidia  filed a shelf registration statement with the US Securities And Exchange Commission Wednesday covering the potential resale of up to 1.1 million common shares of the company by certain stockholders from time to time.The company said it will not receive any proceeds from the sale of the shares as it is not selling the securities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520540108","title":"Q4 2024 Liquidia Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540108","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540108?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 13:01","pubTimestamp":1742446880,"startTime":"0","endTime":"0","summary":"Roger Jeffs; Chief Executive Officer, Director; Liquidia Corp. Michael Kaseta; Chief Financial Officer, Chief Operating Officer; Liquidia Corp. Thank you, Jason. Good morning, everyone, and thank you for joining us today. We believe that 2025 has the potential to be a transformational year for the company as we further build upon the success of 2024, which resulted in the broadening of the tentatively approved label for YUTREPIA to include both the treatment of patients with pulmonary arterial hypertension or PAH and pulmonary hypertension associated with interstitial lung disease or PH-ILD.There are four strategic imperatives that will drive our success and growth, both in the near and long term. These are seeking to obtain final approval and launching new rep in both PAH and PH-ILD as soon as possible after X-ray of the clinical exclusivity on May 23, or just 65 days from now.Secondly, to continue to advance the clinical profile of YUTREPIA to position it as not only the best-in-c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-liquidia-corp-earnings-050120060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LQDA"],"gpt_icon":0},{"id":"2520116185","title":"Needham Raises Liquidia's Price Target to $25 From $19, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2520116185","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520116185?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 02:29","pubTimestamp":1742408964,"startTime":"0","endTime":"0","summary":"Liquidia (LQDA) has an average rating of Buy and mean price target of $24.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA"],"gpt_icon":0},{"id":"1114332801","title":"Stock Track | Liquidia Technologies (LQDA) Plunges 6.24% Pre-Market on Disappointing 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1114332801","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114332801?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:26","pubTimestamp":1742390790,"startTime":"0","endTime":"0","summary":"Shares of Liquidia Technologies Inc  tumbled 6.24% in pre-market trading on Wednesday following the release of the company's full-year 2024 financial results. The biopharmaceutical firm, which specializes in developing therapies for rare cardiopulmonary diseases, reported figures that fell short of analysts' expectations.Liquidia posted a net loss of $130.4 million, or $1.66 per share, for the year 2024, significantly higher than the FactSet estimate of a $1.55 loss per share. Additionally, the ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LQDA"],"gpt_icon":0},{"id":"1137063175","title":"Stock Track | Liquidia Technologies (LQDA) Plunges 6.24% Pre-Market on Wider-Than-Expected 2024 Loss and Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1137063175","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137063175?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:26","pubTimestamp":1742390790,"startTime":"0","endTime":"0","summary":"Shares of Liquidia Technologies Inc  tumbled 6.24% in pre-market trading on Wednesday following the release of its full-year 2024 financial results, which fell short of analysts' expectations. The biopharmaceutical company, focused on developing innovative therapies for rare cardiopulmonary diseases, reported a wider net loss and lower revenue than anticipated.Despite the disappointing financial results, Liquidia provided updates on its product pipeline. The company is targeting final FDA approv","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Liquidia Technologies (LQDA) Plunges 6.24% Pre-Market on Wider-Than-Expected 2024 Loss and Revenue Miss","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LQDA"],"gpt_icon":0},{"id":"2520890541","title":"Liquidia targets final FDA approval of Yutrepia after May 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2520890541","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520890541?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:40","pubTimestamp":1742380833,"startTime":"0","endTime":"0","summary":"Dr. Roger Jeffs, Liquidia’s (LQDA) CEO, said: “Building on our progress this past year, Liquidia has strengthened its financial position, with up t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liquidia-targets-final-fda-approval-of-yutrepia-after-may-23?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liquidia-targets-final-fda-approval-of-yutrepia-after-may-23?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520039709","title":"Earnings Flash (LQDA) Liquidia Posts 2024 Revenue $14M, vs. FactSet Est of $15.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2520039709","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520039709?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:37","pubTimestamp":1742380650,"startTime":"0","endTime":"0","summary":"Earnings Flash (LQDA) Liquidia Posts 2024 Revenue $14M, vs. FactSet Est of $15.9M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA"],"gpt_icon":0},{"id":"2520903972","title":"Earnings Flash (LQDA) Liquidia Posts Full Year 2024 Net Loss $1.66 a Share, vs. FactSet Est of $1.55 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2520903972","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520903972?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:37","pubTimestamp":1742380643,"startTime":"0","endTime":"0","summary":"Earnings Flash (LQDA) Liquidia Posts Full Year 2024 Net Loss $1.66 a Share, vs. FactSet Est of $1.55 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA"],"gpt_icon":0},{"id":"2520133909","title":"Corrected: Liquidia FY Net Income USD -130.4 Million (Corrects Period)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520133909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520133909?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:30","pubTimestamp":1742380201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nPLXAFE168:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520081709","title":"Liquidia Q4 Net Income USD -130.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520081709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520081709?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:30","pubTimestamp":1742380201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nPLXAFE168:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LQDA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.liquidia.com","stockEarnings":[{"period":"1week","weight":-0.013},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.3172},{"period":"6month","weight":0.5225},{"period":"1year","weight":0.0113},{"period":"ytd","weight":0.2959}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06042},{"month":2,"riseRate":0.857143,"avgChangeRate":0.087227},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.040334},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.075222},{"month":5,"riseRate":0.833333,"avgChangeRate":0.15291},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.059983},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.087113},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.013548},{"month":9,"riseRate":0.428571,"avgChangeRate":0.082402},{"month":10,"riseRate":0.571429,"avgChangeRate":0.019418},{"month":11,"riseRate":0.714286,"avgChangeRate":0.037106},{"month":12,"riseRate":0.714286,"avgChangeRate":0.164224}],"exchange":"NASDAQ","name":"Liquidia Technologies Inc","nameEN":"Liquidia Technologies Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Liquidia Technologies Inc(LQDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Liquidia Technologies Inc(LQDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Liquidia Technologies Inc,LQDA,Liquidia Technologies Inc股票,Liquidia Technologies Inc股票老虎,Liquidia Technologies Inc股票老虎国际,Liquidia Technologies Inc行情,Liquidia Technologies Inc股票行情,Liquidia Technologies Inc股价,Liquidia Technologies Inc股市,Liquidia Technologies Inc股票价格,Liquidia Technologies Inc股票交易,Liquidia Technologies Inc股票购买,Liquidia Technologies Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Liquidia Technologies Inc(LQDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Liquidia Technologies Inc(LQDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction